Skip to content
My WebMD Sign In, Sign Up
Font Size

Treat Rheumatoid Arthritis Early

Studies Show Early, Aggressive Treatment May Lead to Remission
By
WebMD Health News

Nov. 13, 2006 (Washington) -- Two studies suggest that treating rheumatoid arthritis (RA) early and aggressively may change its course.

The findings were presented at the 2006 annual meeting of the American College of Rheumatology.

Rheumatoid arthritisis an autoimmune disease caused by the immune system attacking the lining of the joints. It can lead to long-term joint and bone damage and affects 2.1 million Americans, mainly women.

The disease can result in chronic pain, loss of function, and disability, according to the Arthritis Foundation.

There is no cure for the disease. Treatments are aimed at reducing joint inflammation and restoring joint function to near-normal levels.

Early Evidence of Rheumatoid Arthritis

In one study, Dutch researchers studied people with early evidence of rheumatoid arthritis. The researchers show that treating these individuals with the drug methotrexate can possibly prevent the disease from progressing to rheumatoid arthritis.

And in a second study, investigators report that early treatment with methotrexate plus Remicade may result in a drug-free remission in people with rheumatoid arthritis. Remicade is one of a newer category of medications that target specific chemicals that lead to inflammation.

The first study -- called PROMPT -- comprised 110 people with arthritis from an early arthritis clinic in the Netherlands. They received methotrexate or a placebo for one year. Researchers measured joint damage every six months by taking X-rays of the hands and feet -- the joints most commonly affected by rheumatoid arthritis.

People who received methotrexate showed less X-ray damage to the joints after 30 months compared with their counterparts who received a placebo. They were also less likely to develop rheumatoid arthritis, but only if they tested positive for an antibody known as anti-CCP. Anti-CCP antibodies are blood markers that may predict the development of rheumatoid arthritis.

Role of 'Personalized' Medicine

These findings point to a role for personalized medicine, says researcher Tom W.J. Huizinga, MD, chairman of rheumatology at Leiden University Medical Center in the Netherlands. "If you have autoantibodies to anti-CCP and are treated with methotrexate, you don't develop RA," he says.

"The bottom line is that patients should be referred to a rheumatologist early and if they are CCP positive, they should be treated," he says.

Steven B. Abramson, MD, the director of rheumatology at New York University and the Hospital for Joint Diseases in New York City, agrees. "This is a very exciting article [and] it clearly needs to be validated," he says. "This is the beginning of personalized medicine.

"Patients today should want to know if they are CCP positive and if they are, they should make sure their doctors treat them if they have any symptoms," he says.

Today on WebMD

fish oil capsule
Article
senior woman holding green apple
Article
 
young women in yoga class
Video
Man with knee brace
Article
 
Lucille Ball
Slideshow
Hand bones X-ray
Article
 
prescription pills
Article
Woman massaging her neck
Quiz
 
woman roasting vegetables in oven
Slideshow
Woman rubbing shoulder
Slideshow
 
Xray Rheumatoid Arthritis
Slideshow
arthritis
Article